DBV Technologies (XPAR:DBV) 12-1 Month Momentum % : -64.17% (As of May. 17, 2024)

View and export this data going back to 2012. Start your Free Trial

What is DBV Technologies 12-1 Month Momentum %?

12-1 Month Momentum % is the total return of the stock from 12-month ago to 1-month ago. As of today (2024-05-17), DBV Technologies's 12-1 Month Momentum % is -64.17%.

The industry rank for DBV Technologies's 12-1 Month Momentum % or its related term are showing as below:

XPAR:DBV's 12-1 Month Momentum % is ranked worse than
82.14% of 1484 companies
in the Biotechnology industry
Industry Median: -26.52 vs XPAR:DBV: -64.17

Competitive Comparison of DBV Technologies's 12-1 Month Momentum %

For the Biotechnology subindustry, DBV Technologies's 12-1 Month Momentum %, along with its competitors' market caps and 12-1 Month Momentum % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

DBV Technologies's 12-1 Month Momentum % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, DBV Technologies's 12-1 Month Momentum % distribution charts can be found below:

* The bar in red indicates where DBV Technologies's 12-1 Month Momentum % falls into.

DBV Technologies (XPAR:DBV) 12-1 Month Momentum % Calculation

12-1 Month Momentum % is calculated as following:

12-1 Month Momentum %

( Price 1-month ago

Price 12-month ago

- 1 )

100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

DBV Technologies (XPAR:DBV) 12-1 Month Momentum % Explanation

Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 12-1 Month Momentum % measures the total return to a stock over the past twelve months, but ignores the previous month.

The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.

DBV Technologies 12-1 Month Momentum % Related Terms

Thank you for viewing the detailed overview of DBV Technologies's 12-1 Month Momentum % provided by GuruFocus.com. Please click on the following links to see related term pages.

DBV Technologies (XPAR:DBV) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » DBV Technologies SA (XPAR:DBV) » Definitions » 12-1 Month Momentum %

Comparable Companies

Traded in Other Exchanges

DBVT:USA 0QAJ:UK DBV:Germany

Address

177-181 avenue Pierre Brossolette, Montrouge, FRA, 92120

Website

http://www.dbvtechnologies.com

DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Viaskin targets specific antigen-presenting immune cells in the skin, called Langerhans cells, that capture the antigen and migrate to the lymph node in order to activate the immune system without passage of the antigen into the bloodstream, minimizing systemic exposure in the body. Its main product candidate is Viaskin Peanut for the treatment of peanut-allergic patients.